Cited by 217Renal Diseases and GlomerulopathiesChronic Kidney Disease and DiabetesAcute Kidney Injury Research

The DOI matches its Crossref record, with a small difference in title or year; 167 of the 168 references it cites were found in a registry or an index.

Management of Glomerular Proteinuria: A Commentary

Wilmer, William A., Rovin, Brad H., Hebert, Christopher J., Rao, Sunil V., Kumor, Karen, Hebert, Lee A.·2003·Journal of the American Society of Nephrology

DOI 10.1097/01.asn.0000100145.27188.33

Open this paper in CoChat — free account

Abstract

It is widely accepted that proteinuria reduction is an appropriate therapeutic goal in chronic proteinuric kidney disease. Based on large randomized controlled clinical trials (RCT), ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB) therapy have emerged as the most important antiproteinuric and renal protective interventions. However, there are numerous other interventions that have been shown to be antiproteinuric and, therefore, likely to be renoprotective. Unfortunately testing each of these antiproteinuric therapies in RCT is not feasible. The nephrologist has two choices: restrict antiproteinuric therapies to those shown to be effective in RCT or expand the use of antiproteinuric therapies to include those that, although unproven, are plausibly effective and prudent to use. The goal of this work is to provide the documentation needed for the nephrologist to choose between these strategies. This work describes 25 separate interventions that are either antiproteinuric or may block injurious mechanisms of proteinuria. Each intervention is assigned a level of recommendation (Level 1 is the highest; Level 3 is the lowest) according to the strength of the evidence supporting its antiproteinuric and renoprotective efficacy. Pathophysiologic mechanisms possibly involved are also discussed. The number of interventions at each level of recommendation are: Level 1, n = 7; Level 2, n = 9; Level 3, n = 9. Our experience indicates that we can achieve in most patients the maj…

Integrity signals

Registry

Crossref · 10.1097/01.asn.0000100145.27188.33

Cites

167 of 167 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

RETRACTED: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial
Nakao, N., Yoshimura, A., Morita, H., Takada, M., Kayano, T., & Ideura, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12229-5 · Cited by 947
Retracted
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies
(2002) · The Lancet · doi:10.1016/s0140-6736(02)11911-8 · Cited by 10,266
Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,527
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals
Gerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440
The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease
Klahr, S., Levey, A. S., Beck, G. J., Caggiula, A. W., Hunsicker, L., Kusek, J. W., & Striker, G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403313301301 · Cited by 2,328
Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney Disease Results From the AASK Trial
Wright, J. T. (2002) · JAMA · doi:10.1001/jama.288.19.2421 · Cited by 2,039
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
The GISEN Group, & MANNO, C. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11445-8 · Cited by 1,863
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials
(2000) · The Lancet · doi:10.1016/s0140-6736(00)03307-9 · Cited by 1,790
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients
Flather, M. D., Yusuf, S., Køber, L., Pfeffer, M. A., Hall, A. S., Murray, G. D., Torp-Pedersen, C. T., Ball, S. G., Pogue, J. M., Moyé, L. A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02212-1 · Cited by 1,585
MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09328-5 · Cited by 1,502
Preserving renal function in adults with hypertension and diabetes: A consensus approach
Bakris, G. L., Williams, M. E., Dworkin, L. D., Elliott, W. J., Epstein, M., Toto, R. D., Tuttle, K. R., Douglas, J. G., Hsueh, W. A., & Sowers, J. R. (2000) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2000.16225 · Cited by 1,396
Walking Compared with Vigorous Exercise for the Prevention of Cardiovascular Events in Women
Manson, J. E., Greenland, P., LaCroix, A. Z., Stefanick, M. L., Mouton, C. P., Oberman, A., Perri, M. G., Sheps, D. S., Pettinger, M. B., & Siscovick, D. S. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021067 · Cited by 1,349
Blood Pressure Control, Proteinuria, and the Progression of Renal Disease
Peterson, J. C., Adler, S., Burkart, J. M., Greene, T., Hebert, L. A., Hunsicker, L. G., King, A. J., Klahr, S., Massry, S. G., Seifter, J. L., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-10-199511150-00003 · Cited by 1,325
Self-citation
A Role for Uric Acid in the Progression of Renal Disease
Kang, D., Nakagawa, T., Feng, L., Watanabe, S., Han, L., Mazzali, M., Truong, L. D., Harris, R. C., & Johnson, R. J. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000034910.58454.fd · Cited by 1,306
Obesity-related glomerulopathy: An emerging epidemic
Kambham, N., Markowitz, G. S., Valeri, A. M., Lin, J., & D’Agati, V. D. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.0590041498.x · Cited by 1,288
Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial
Dickstein, K., & KJEKSHUS, J. K. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09895-1 · Cited by 1,200
A Comparison of Outcomes with Angiotensin-Converting–Enzyme Inhibitors and Diuretics for Hypertension in the Elderly
Wing, L. M. H., Reid, C. M., Ryan, P., Beilin, L. J., Brown, M. A., Jennings, G. L. R., Johnston, C. I., McNeil, J. J., Macdonald, G. J., Marley, J. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021716 · Cited by 1,130
Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease: A Meta-Analysis of Patient-Level Data
Jafar, T. H., Schmid, C. H., Landa, M., Giatras, I., Toto, R., Remuzzi, G., Maschio, G., Brenner, B. M., Kamper, A., Zucchelli, P., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-2-200107170-00007 · Cited by 1,092
Prognostic Value of Ambulatory Blood-Pressure Recordings in Patients with Treated Hypertension
Clement, D. L., De Buyzere, M. L., De Bacquer, D. A., de Leeuw, P. W., Duprez, D. A., Fagard, R. H., Gheeraert, P. J., Missault, L. H., Braun, J. J., Six, R. O., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022273 · Cited by 1,085
CHARM IN-VESTIGATORS AND COMMITTEES. EFFECTS OF CANDESARTAN IN PATIENTS WITH CHRONIC HEART FAILURE AND REDUCED LEFT-VENTRICULAR SYSTOLIC FUNCTION TAKING ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS: THE CHARM-ADDED TRIAL
McMurray, J. J. V., Östergren, J., Swedberg, K. B., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer (2003) · The Lancet · Cited by 1,043
Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study
Mogensen, C. E., Neldam, S., Tikkanen, I., Oren, S., Viskoper, R. J., Watts, R. W., & Cooper, M. E. (2000) · BMJ · doi:10.1136/bmj.321.7274.1440 · Cited by 1,026
Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes
Schrier, R. W., Estacio, R. O., Esler, A. L., & Mehler, P. S. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00213.x · Cited by 837
Renal Insufficiency and Subsequent Death Resulting from Cardiovascular Disease in the United States
Muntner, P., He, J., Hamm, L. L., Loria, C. M., & Whelton, P. K. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v133745 · Cited by 825
Increase in Nocturnal Blood Pressure and Progression to Microalbuminuria in Type 1 Diabetes
Lurbe, E., Redón, J., Kesani, A., Pascual, J. M., Tacons, J., Álvarez, V., & BATLLE, D. C. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013410 · Cited by 723
Angiotensin II receptors
Singh, K. D., & Karnik, S. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816228-6.00020-9 · Cited by 704
Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study
Modification of Diet in Renal Disease Study Group, Hunsicker, L. G., Adler, S. G., Caggiula, A. W., England, B. K., Greene, T., Kusek, J. W., Rogers, N. L., Teschan, P. E., & Beck, G. J. (1997) · Kidney International · doi:10.1038/ki.1997.260 · Cited by 698
Untitled work
(2000) · PubMed · Cited by 691
Effect of lipid reduction on the progression of renal disease: A meta-analysis
Fried, L. F., Orchard, T. J., & Kasiske, B. L. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00487.x · Cited by 662
Understanding the nature of renal disease progression
Remuzzi, G., Ruggenenti, P. L., & Benigni, A. (1997) · Kidney International · doi:10.1038/ki.1997.2 · Cited by 641
Early prediction of severity in acute pancreatitis by urinary trypsinogen activation peptide: a multicentre study
Neoptolemos, J. P., KEMPPAINEN, E., Mayer, J., Fitzpatrick, J., Raraty, M. G. T., Slavin, J. P., Beger, H.-G., Hietaranta, A. J., & Pa, P. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02327-8 · Cited by 621
Nephropathy in Patients with Type 2 Diabetes
Remuzzi, G., Schieppati, A., & Ruggenenti, P. L. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp011773 · Cited by 585
Measurement of renal function in chronic renal disease
Levey, P. D. A. S. (1990) · Kidney International · doi:10.1038/ki.1990.182 · Cited by 564
Uric Acid, Hominoid Evolution, and the Pathogenesis of Salt-Sensitivity
Watanabe, S., Kang, D., Feng, L., Nakagawa, T., Kanellis, J., Lan, H. Y., Mazzali, M., & Johnson, R. J. (2002) · Hypertension · doi:10.1161/01.hyp.0000028589.66335.aa · Cited by 562
Progression, remission, regression of chronic renal diseases
Ruggenenti, P. L., Schieppati, A., & Remuzzi, G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04728-0 · Cited by 545
The Effects of Weight Loss on Renal Function in Patients with Severe Obesity
Chagnac, A., Weinstein, T., Herman, M., Hirsh, J., Gafter, U., & Ori, Y. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000068462.38661.89 · Cited by 537
Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure
Farquharson, C. A. J., Butler, R., Hill, A., Belch, J. J. F., & Struthers, A. D. (2002) · Circulation · doi:10.1161/01.cir.0000022140.61460.1d · Cited by 504
Mineralocorticoid Blockade Reduces Vascular Injury in Stroke-Prone Hypertensive Rats
Rocha, R., Chander, P. N., Khanna, K., Zuckerman, A. L., & Stier, C. T. (1998) · Hypertension · doi:10.1161/01.hyp.31.1.451 · Cited by 492
Comparative Effects of Ramipril on Ambulatory and Office Blood Pressures
Svensson, P., Fairé, U. D., Sleight, P., Yusuf, S., & Östergren, J. (2001) · Hypertension · doi:10.1161/hy1101.099502 · Cited by 490
Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy
Sato, A., Hayashi, K., Naruse, M., & Saruta, T. (2003) · Hypertension · doi:10.1161/01.hyp.0000044937.95080.e9 · Cited by 466 · cited 1×
“Eplerenone (currently under study) is similar to that of spironolactone, but with fewer side effects (128), and is antiproteinuric (129,130).”
Background
Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS
Pifer, T. B., McCullough, K. P., Port, F. K., Goodkin, D. A., Maroni, B. J., Held, P. J., & Young, E. W. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00658.x · Cited by 459
The Modification of Diet in Renal Disease Study
Klahr, S. (1989) · New England Journal of Medicine · doi:10.1056/nejm198903303201310 · Cited by 454
Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists
Taal, M. W., & Brenner, B. M. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00031.x · Cited by 439
Effect of Angiotensin-Converting Enzyme Inhibitors on the Progression of Nondiabetic Renal Disease
Giatras, I., Lau, J., & Levey, A. S. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-5-199709010-00001 · Cited by 429
Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy
Berl, T., Hunsicker, L. G., Lewis, J. B., Pfeffer, M. A., Porush, J. G., Rouleau, J. L., Drury, P., Esmatjes, E., Hricik, D. E., Parikh, C. R., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-7-200304010-00010 · Cited by 400
Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension
Weinberger, M. H., Roniker, B., Krause, S. L., & Weiss, R. (2002) · American Journal of Hypertension · doi:10.1016/s0895-7061(02)02957-6 · Cited by 386
Treatment of IgA Nephropathy with ACE Inhibitors: A Randomized and Controlled Trial
Praga, M., Gutiérrez, E., González, E., Morales, E., & Hernández, E. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000068460.37369.dc · Cited by 345
Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy
Hansen, H. P., Tauber-Lassen, E., Jensen, B. R., & Parving, H. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00421.x · Cited by 331
A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease
Bianchi, S., Bigazzi, R., Caiazza, A., & Campese, V. M. (2003) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2003.50140 · Cited by 329
Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies
Morales, E., Valero, M. A., León, M., Hernández, E., & Praga, M. (2003) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2003.50039 · Cited by 320
Effect of Pravastatin on Loss of Renal Function in People with Moderate Chronic Renal Insufficiency and Cardiovascular Disease
Tonelli, M. A., Moyé, L. A., Sacks, F. M., Cole, T., & Curhan, G. C. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000068461.45784.2f · Cited by 299
Smoking Is Related to Albuminuria and Abnormal Renal Function in Nondiabetic Persons
Pinto‐Sietsma, S., Mulder, J., Janssen, W. M. T., Hillege, H. L., de Zeeuw, D., & de Jong, P. E. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-8-200010170-00008 · Cited by 295
J-Shaped Relationship between Blood Pressure and Mortality in Hypertensive Patients: New Insights from a Meta-Analysis of Individual-Patient Data
Boutitie, F., Gueyffier, F., Pocock, S., Fagard, R. H., & Boissel, J. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-6-200203190-00007 · Cited by 286
Retarding progression of chronic renal disease: The neglected issue of residual proteinuria
Ruggenenti, P. L., Perna, A., Remuzzi, G., & Investigators of the Gisen Group (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00033.x · Cited by 271
The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice.
Esther, C. R., Marino, E. M., Howard, T. E., Machaud, A., Corvol, P. L., Capecchi, M. R., & Bernstein, K. E. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119419 · Cited by 271
Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes
Ruggenenti, P., Gaspari, F., Perna, A., & Remuzzi, G. (1998) · BMJ · doi:10.1136/bmj.316.7130.504 · Cited by 264
Spironolactone in Addition to ACE Inhibition to Reduce Proteinuria in Patients with Chronic Renal Disease
Chrysostomou, A., & Becker, G. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200109203451215 · Cited by 264
Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases
Schepkens, H., Vanholder, R. C., Billiouw, J.-M., & Lameire, N. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00642-8 · Cited by 255
ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure
Bakris, G. L., Siomos, M. Z., Richardson, D., Janssen, İ., Bolton, W. K., Hebert, L. A., Agarwal, R., & Catanzaro, D. F. (2000) · Kidney International · doi:10.1111/j.1523-1755.2000.00381.x · Cited by 247
Self-citation
Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy
Jacobsen, P. K., Andersen, S., Rossing, K., Jensen, B. R., & Parving, H. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00940.x · Cited by 224
Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces.
Dell’Italia, L. J., Meng, Q. C., Balcells, E., Wei, C., Palmer, R., Hageman, G. R., Durand, J., Hankes, G. H., & Oparil, S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119529 · Cited by 217
Prevention of glomerular dysfunction in diabetic rats by treatment with d-alpha-tocopherol.
Koya, D., Lee, I. K., Ishii, H., Kanoh, H., & King, G. L. (1997) · Journal of the American Society of Nephrology · doi:10.1681/asn.v83426 · Cited by 216
Renal dysfunction accompanying oral creatine supplements
Pritchard, N., & Kalra, P. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79319-3 · Cited by 213
Renal handling of albumin: A critical review of basic concepts and perspective
Russo, L. M., Bakris, G. L., & Comper, W. D. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.32764 · Cited by 208
The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide
Buter, H. (1998) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/13.7.1682 · Cited by 198
Cardiac and Renal Effects of Standard Versus Rigorous Blood Pressure Control in Autosomal-Dominant Polycystic Kidney Disease
Schrier, R. W., McFann, K. K., Johnson, A., Chapman, A. B., Edelstein, C. L., Brosnahan, G., Ecder, T., & Tison, L. O. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000018407.60002.b9 · Cited by 197
The Living Donor in Kidney Transplantation
Bay, W. H., & HEBERT, L. A. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-5-719 · Cited by 197
Self-citation
Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment
Rossing, P. R., Hommel, E. E., Smidt, U., & Parving, H. ‐. (1994) · Diabetologia · doi:10.1007/s001250050140 · Cited by 190
Plasminogen activator inhibitor-1 and the kidney
Eddy, A. A. (2002) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00032.2002 · Cited by 188
Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies
Campbell, R. C., Sangalli, F., Perticucci, E., Aros, C., Viscarra, C., Perna, A., Remuzzi, A., Bertocchi, F., Fagiani, L., Remuzzi, G., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00832.x · Cited by 186
Renoprotection: One or many therapies?
Hebert, L. A., Wilmer, W. A., Falkenhain, M. E., Ladson-Wofford, S. E., Nahman, N. S., & Rovin, B. H. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.0590041211.x · Cited by 186
Self-citation
Fenofibrate Increases Creatininemia by Increasing Metabolic Production of Creatinine
Hottelart, C., El Esper, N., Rose, F., Achard, J.-M., & Fournier, A. (2002) · Nephron · doi:10.1159/000064083 · Cited by 186
Complement Activation Products in the Urine from Proteinuric Patients
Morita, Y., Ikeguchi, H., Nakamura, J., Hotta, N., Yuzawa, Y., & Matsuo, S. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v114700 · Cited by 186
Smoking and the Kidney
Orth, S. R. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000018401.82863.fd · Cited by 178
Inter-arm differences in blood pressure: when are they clinically significant?
Lane, D. A., Beevers, M., Barnes, N., Bourne, J., John, A., Malins, S., & Beevers, D. G. (2002) · Journal of Hypertension · doi:10.1097/00004872-200206000-00019 · Cited by 176
Regression of left ventricular hypertrophy in human hypertension with irbesartan
Malmqvist, K. K., Kahan, T., Edner, M., Held, C., Hägg, A., Lind, L., Müller-Brunotte, R., Nyström, F. H., Öhman, K. P., Osbakken, M. D., et al. (2001) · Journal of Hypertension · doi:10.1097/00004872-200106000-00023 · Cited by 176
Chronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury
Ruggenenti, P. L., Perna, A., Gherardi, G., Benini, R., & Remuzzi, G. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70054-0 · Cited by 175
Dual renin-angiotensin system blockade at optimal doses for proteinuria
Laverman, G. D., Navis, G. J., Henning, R. H., de Jong, P. E., & de Zeeuw, D. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00536.x · Cited by 167
In vivo bradykinin B2 receptor activation reduces renal fibrosis
Schanstra, J. P., Neau, E., Drogoz, P., Arévalo-Gómez, M. A., López-Novoa, J. M., Calise, D., Pécher, C., Bäder, M., Girolami, J., & Bascands, J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15493 · Cited by 166
“Strict” blood pressure control and progression of renal disease in hypertensive nephrosclerosis
Toto, R. D., Mitchell, H. C., Smith, R. D., Lee, H.-C., McIntire, D. D., & Pettinger, W. A. (1995) · Kidney International · doi:10.1038/ki.1995.361 · Cited by 164
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial
Wright, J., Bakris, G. L., & Greene, T. (2003) · ACC Current Journal Review · doi:10.1016/s1062-1458(03)00035-7 · Cited by 161
Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications
Epstein, M. (2001) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(01)80115-3 · Cited by 157
Proteinuria: Its clinical importance and role in progressive renal disease
Keane, W. F. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70237-x · Cited by 150
High urine volume and low urine osmolality are risk factors for faster progression of renal disease
Hebert, L. A., Greene, T., Levey, A. S., Falkenhain, M. E., & Klahr, S. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00193-8 · Cited by 134
Self-citation
Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension
Pedrinelli, R., Dell’Omo, G., Bello, V. D., Pontremoli, R., & Mariani, M. (2002) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001316 · Cited by 134
The Verdict From ALLHAT—Thiazide Diuretics Are the Preferred Initial Therapy for Hypertension
Appel, L. J. (2002) · JAMA · doi:10.1001/jama.288.23.3039 · Cited by 130
Effects of supplementation with vitamin C or E on albuminuria, glomerular TGF-beta, and glomerular size in diabetes.
Craven, P. A., DeRubertis, F. R., Kagan, V. E., Melhem, M. F., & Studer, R. (1997) · Journal of the American Society of Nephrology · doi:10.1681/asn.v891405 · Cited by 129
The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy
Rodby, R. A., Rohde, R. D., Sharon, Z., Pohl, M. A., Bain, R. P., & Lewis, E. J. (1995) · American Journal of Kidney Diseases · doi:10.1016/0272-6386(95)90054-3 · Cited by 128
Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN).
Ruggenenti, P. L., Perna, A., Benini, R., & Remuzzi, G. (1998) · Journal of the American Society of Nephrology · doi:10.1681/asn.v9112096 · Cited by 127
ACE Inhibitors versus AT1 Receptor Antagonists in Patients with Chronic Renal Disease
Hilgers, K. F., & Mann, J. F. E. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1341100 · Cited by 126
C6 Mediates Chronic Progression of Tubulointerstitial Damage in Rats with Remnant Kidneys
Nangaku, M., Pippin, J. W., & Couser, W. G. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v134928 · Cited by 125
Remission of nephrotic range proteinuria in type I diabetes
Hebert, L. A., Bain, R. P., Verme, D., Cattran, D. C., Whittier, F. C., Tolchin, N., Rohde, R. D., Lewis, E. J., Lewis, E. J., Rohde, R., et al. (1994) · Kidney International · doi:10.1038/ki.1994.469 · Cited by 124
Self-citation
Oral Contraceptive Use and Hormone Replacement Therapy Are Associated With Microalbuminuria
Monster, T. B. M. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.16.2000 · Cited by 120
Effect of combining ACE inhibitor and statin in severe experimental nephropathy
Zoja, C., Corna, D., Rottoli, D., Cattaneo, D., Zanchi, C., Tomasoni, S., Abbate, M., & Remuzzi, G. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00332.x · Cited by 116
Pentoxifylline Attenuated the Renal Disease Progression in Rats with Remnant Kidney
Lin, S., Chen, Y., Chien, C., Chiang, W., Tsai, C.-C., & Tsai, T. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000034909.10994.8a · Cited by 114
Effects of Dietary Supplementation of α-Lipoic Acid on Early Glomerular Injury in Diabetes Mellitus
Melhem, M. F., Craven, P. A., & DeRubertis, F. R. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v121124 · Cited by 113
Effect of Pravastatin on Proteinuria in Patients With Well-Controlled Hypertension
Lee, T., Su, S.-F., & Tsai, C. (2002) · Hypertension · doi:10.1161/01.hyp.0000022805.11288.7f · Cited by 113
Lowering of Microalbuminuria in Diabetic Patients by a Sympathicoplegic Agent: Novel Approach to Prevent Progression of Diabetic Nephropathy?
STROJEK, K., GRZESZCZAK, W., GÓRSKA, J., LESCHINGER, M. I., & RITZ, E. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v123602 · Cited by 112
Role of complement in acute tubulointerstitial injury of rats with aminonucleoside nephrosis.
Nomura, A., Morita, Y., Maruyama, S., Hotta, N., Nadai, M., Wang, L., Hasegawa, T., & Matsuo, S. (1997) · Europe PMC (PubMed Central) · Cited by 108
Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).
Ruggenenti, P. L., Perna, A., Mosconi, L., Matalone, M., Pisoni, R. L., Gaspari, F., & Remuzzi, G. (1997) · PubMed · Cited by 106
Combination ACE Inhibitor and Angiotensin II Receptor Antagonist Therapy in Diabetic Nephropathy
Hebert, L. A., Falkenhain, M. E., Nahman, N. S., Cosio, F. G., & O’Dorisio, T. M. (1999) · American Journal of Nephrology · doi:10.1159/000013417 · Cited by 105
Self-citation
Chronic Proteinuric Nephropathies. II. Outcomes and Response to Treatment in a Prospective Cohort of 352 Patients
Ruggenenti, P. L., Perna, A., Zoccali, C., Gherardi, G., Benini, R., Testa, A., & Remuzzi, G. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v11188 · Cited by 104
Renoprotective therapy: titration against urinary protein excretion
de Jong, P. E., Navis, G. J., & de Zeeuw, D. (1999) · The Lancet · doi:10.1016/s0140-6736(99)90122-8 · Cited by 103
Renal Interstitial Fluid Angiotensin I and Angiotensin II Concentrations during Local Angiotensin-Converting Enzyme Inhibition
Nishiyama, A., Seth, D. M., & Navar, L. G. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000026610.48842.cb · Cited by 103
Dietary phytoestrogens: A possible role in renal disease protection
Velasquez, M. T., & Bhathena, S. J. (2001) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(05)80025-3 · Cited by 101
and Vitamin B
Bjorkman, D. (2000) · Journal watch · doi:10.1056/jg200008010000003 · Cited by 96
Proteinuria and Phenotypic Change of Proximal Tubular Cells
Zoja, C., Morigi, M., & Remuzzi, G. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000068626.23485.e0 · Cited by 96
Angiotensin-converting enzyme in non-neoplastic kidney diseases
Metzger, R. P., Bohle, R. M., Pauls, K., Eichner, G., Alhenc‐Gelas, F., Danilov, S. M., & Franke, F. E. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00660.x · Cited by 95
Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift
Epstein, M. (2001) · Journal of Hypertension · doi:10.1097/00004872-200105000-00001 · Cited by 87
Measurement of SC5b-9 in urine in patients with the nephrotic syndrome
Ogrodowski, J. L., Hebert, L. A., Sedmak, D. D., Cosio, F. G., Tamerius, J. D., & Kolb, W. P. (1991) · Kidney International · doi:10.1038/ki.1991.326 · Cited by 83
Self-citation
Comparison of Nifedipine Alone and With Diltiazem or Verapamil in Hypertension
Saseen, J. J., Carter, B. L., Brown, T. E., Elliott, W. J., & Black, H. R. (1996) · Hypertension · doi:10.1161/01.hyp.28.1.109 · Cited by 82
The role of complement in the pathogenesis of tubulointerstitial lesions in rat mesangial proliferative glomerulonephritis.
Morita, Y., Nomura, A., Yuzawa, Y., Nishikawa, K., Hotta, N., Shimizu, F., & Matsuo, S. (1997) · Journal of the American Society of Nephrology · doi:10.1681/asn.v891363 · Cited by 82
Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention. the swiss heart study: a randomized controlled trial
Schnyder, G., Roffi, M., Flammer, Y., Pin, R., & Hess, O. M. (2003) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)01039-5 · Cited by 76
Urea and Creatinine Production and Excretion in Urine during and after Prolonged Heavy Exercise
Refsum, H. E., & Strømme, S. B. (1974) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365517409082493 · Cited by 74
Diverse Effects of Increasing Lisinopril Doses on Lipid Abnormalities in Chronic Nephropathies
Ruggenenti, P. L., Mise, N., Pisoni, R., Arnoldi, F., Pezzotta, A., Perna, A., Cattaneo, D., & Remuzzi, G. (2003) · Circulation · doi:10.1161/01.cir.0000047526.08376.80 · Cited by 71
Glomerular Permselectivity Factors Are Not Responsible for the Increase in Fractional Clearance of Albumin in Rat Glomerulonephritis
Greive, K. A., Nikolic‐Paterson, D. J., Guimarães, M. A. M., Nikolovski, J., Pratt, L. M., Mu, W., Atkins, R. C., & Comper, W. D. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61792-0 · Cited by 65
Mycophenolate mofetil prevents arteriolopathy and renal injury in subtotal ablation despite persistent hypertension
Tapia, E., Franco, M., Sánchez‐Lozada, L. G., Soto, V., Ávila-Casado, C., Santamaría, J., Quiroz, Y., Rodríguez‐Iturbe, B., & Herrera-Acosta, J. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00811.x · Cited by 65
Bradykinin-Induced Reductions in Collagen Gene Expression Involve Prostacyclin
Gallagher, A. M., Yu, H., & Printz, M. P. (1998) · Hypertension · doi:10.1161/01.hyp.32.1.84 · Cited by 64
Rethinking Postmenopausal Hormone Therapy
Solomon, C. G., & Dluhy, R. G. (2003) · New England Journal of Medicine · doi:10.1056/nejmp030006 · Cited by 64
Long-term caffeine consumption exacerbates renal failure in obese, diabetic, ZSF1 (fa-facp) rats
Tofovic, S. P., Kost, C. K., Jackson, E. K., & Bastacky, S. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00278.x · Cited by 63
Cigarette smoke condensate aggravates renal injury in the renal ablation model
Odoni, G., Ogata, E., Viedt, C., Amann, K., Ritz, E., & Orth, S. R. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00382.x · Cited by 63
Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure
Farquharson, C. A. J., & Struthers, A. D. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01689-3 · Cited by 61
Proteinuria is preceded by decreased nitric oxide synthesis and prevented by a NO donor in cholesterol-fed rats
Attia, D. M., Ni, Z., de Boer, P., Attia, M. A., Goldschmeding, R., Koomans, H. A., Vaziri, N. D., & Joles, J. A. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00313.x · Cited by 61
Long-Term Renoprotective Effects of Losartan in Diabetic Nephropathy
Andersen, S., Tarnow, L., Cambien, F., Rossing, P. R., Juhl, T. R., Deinum, J., & Parving, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1501 · Cited by 58
A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease
Vasavada, N., Saha, C., & Agarwal, R. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00124.x · Cited by 56
High protein-induced glomerular hypertrophy is vascular endothelial growth factor-dependent
Schrijvers, B. F., Rasch, R., Tilton, R. G., & Flyvbjerg, A. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00310.x · Cited by 55
Effects of dietary protein restriction on fibrinogen and albumin metabolism in nephrotic patients
Giordano, M., Feo, P. D., Lucidi, P., dePascale, E., Giordano, G., Cirillo, D., Dardo, G., Signorelli, S. S., & Castellino, P. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00791.x · Cited by 55
Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status.
van der Kleij, F. G., Schmidt, A., Navis, G., Haas, M., Yilmaz, N., de Jong, P. E., Mayer, G. J., & de Zeeuw, D. (1997) · PubMed · Cited by 55
Impact of Treatment of Dyslipidemia on Renal Function, Fat Deposits and Scarring in Patients with Persistent Nephrotic Syndrome
Gheith, O. A. A., Sobh, M. A. K., Mohamed, K. E.-S., El-Baz, M. A., El-Husseini, F., Gazarin, S. S., Ahmed, H. A.-E.-H., Rasem, M. W., & Amer, G. M. (2002) · The Nephron journals/Nephron journals · doi:10.1159/000065021 · Cited by 53
The ALLHAT Report: A Case of Information and Misinformation
Weber, M. A. (2003) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2003.02287.x · Cited by 51
Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies
Ruggenenti, P., Perna, A., Mosconi, L., Matalone, M., Pisoni, R., Gaspari, F., & Remuzzi, G. (1997) · Kidney International · Cited by 50
Transferrin but not albumin mediates stimulation of complement C3 biosynthesis in human proximal tubular epithelial cells
Tang, S. C. W., Lai, K. N., Chan, T. M., Lan, H. Y., Ho, S. K., & Sacks, S. H. (2001) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2001.20593 · Cited by 49
A circadian rhythm of proteinuria in patients with a nephrotic syndrome
Koopman, M. G., Krediet, R. T., Zuyderhoudt, F. M. J., de Moor, E., & Arisz, L. (1985) · Clinical Science · doi:10.1042/cs0690395 · Cited by 48
Treatment of Severe Nephrotic Syndrome With Meclofenamate: An Uncontrolled Pilot Study
Velosa, J. A., Torres, V. E., Donadío, J. V., Wagoner, R. D., Holley, K. E., & Offord, K. P. (1985) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60980-x · Cited by 40
ACE gene polymorphism and progression of diabetic nephropathy in Korean type 2 diabetic patients: effect of ACE gene DD on the progression of diabetic nephropathy
Ha, S., Park, H. C., Park, H. S., Kang, B. S., Lee, T. H., Hwang, H. J., Kim, S. J., Kim, D. H., Kang, S., Choi, K. H., et al. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00191-4 · Cited by 37
Eplerenone reduces proteinuria in type II diabetes mellitus: implications for aldosterone involvement in the pathogenesis of renal dysfunction
Epstein, M., Buckalew, V. M., Altamirano, J. H., Roniker, B., Krause, S. L., & Kleiman, J. H. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)81115-9 · Cited by 36
Familial nephropathy differing from minimal change nephropathy and focal glomerulosclerosis
Branten, A. J. W., van den Born, J., Jansen, J. L. J., Assmann, K. J. M., Wetzels, J. F. M., & Dijkman, W. T. T. A. O. H. B. P. M. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.059002693.x · Cited by 35
Sodium bicarbonate treatment reduces renal injury, renal production of transforming growth Factor-β, and urinary transforming growth Factor-β excretion in rats with doxorubicin-induced nephropathy
Baroni, E. A., Costa, R. S., Volpini, R. A., & Coimbra, T. M. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70363-x · Cited by 34
Maximal suppression of renin-angiotensin system in nonproliferative glomerulonephritis
Iodice, C., Balletta, M., Minutolo, R., Giannattasio, P., Tuccillo, S., Bellizzi, V., D’Amora, M., Rinaldi, G., Signoriello, G., Conte, G., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00015.x · Cited by 34
Renoprotective effects of losartan in diabetic nephropathy: Interaction with ACE insertion/deletion genotype?
Andersen, S., Tarnow, L., Cambien, F., Rossing, P. R., Juhl, T. R., Deinum, J., & Parving, H. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00410.x · Cited by 33
Are COX-2 selective inhibitors nephrotoxic?
Mj, D. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70274-5 · Cited by 33
The Expanding Role of Angiotensin Converting Enzyme Inhibitors in the Management of Hypertension
Burris, J. F. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb04070.x · Cited by 32
Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial
Owada, A., Suda, S., & Hata, T. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01567-x · Cited by 30
Effect of selenium-deficient diet in experimental glomerular disease
Baliga, R., Baliga, M., & Shah, S. V. (1992) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1992.263.1.f56 · Cited by 30
Dietary protein intake significantly affects the serum creatinine concentration
Butani, L., Polinsky, M. S., Kaiser, B. A., & Baluarte, H. J. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00342.x · Cited by 29
Circadian rhythm in glomerular transport of macromolecules through large pores and shunt pathway
Koopman, M. G., Koomen, G. C. M., van Acker, B. A. C., & Arisz, L. (1996) · Kidney International · doi:10.1038/ki.1996.178 · Cited by 28
Effect of high dose ramipril with or without indomethacin on glomerular selectivity
Pisoni, R., Ruggenenti, P. L., Sangalli, F., Lepre, M. S., Remuzzi, A., & Remuzzi, G. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00535.x · Cited by 26
ACUTE AND CHRONIC EFFECTS OF ANGIOTENSIN‐CONVERTING ENZYME INHIBITORS ON TISSUE ANGIOTENSIN‐CONVERTING ENZYME
Chai, S. Y., Perich, R. B., Jackson, B., Mendelsohn, F. A. O., & Johnston, C. I. (1992) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1992.tb02803.x · Cited by 26
Kidney iron status in passive Heymann nephritis and the effect of an iron-deficient diet.
Baliga, R., Ueda, N., & Shah, S. V. (1996) · Journal of the American Society of Nephrology · doi:10.1681/asn.v781183 · Cited by 24
Adverse Effect of Exercise on Immune Complex-Mediated Glomerulonephritis
Cornacoff, J. B., Hebert, L. A., Sharma, H. M., Bay, W. H., & Young, D. C. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000183481 · Cited by 24
Self-citation
Antiproteinuric versus antihypertensive effects of high-dose ACE inhibitor therapy
Haas, M., Leko-Mohr, Z., Erler, C., & Mayer, G. J. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.34883 · Cited by 24
Doxazosin, but not amlodipine decreases insulin resistance in patients with chronic renal failure: a prospective, randomized-controlled study
Yıldız, A., Hursit, M., Celik, A., Kayacan, S. M., Yazıcı, H., Akkaya, V., Gurol, A., & Karsidag, K. (2002) · Clinical Nephrology · doi:10.5414/cnp58405 · Cited by 17
MRC/BHF Heart Protection Study
Collins, R., Armitage, J., Parish, S., Sleight, P., & Peto, R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11692-8 · Cited by 13
High-dose ACE inhibition: Can it improve renoprotection?
Navis, G. J., Kramer, A. B., & de Jong, P. E. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.36005 · Cited by 13
Attenuating effect of a semipurified alcohol extract of soy protein on glomerular injury in spontaneous hypercholesterolemic male Imai rats
Sakemi, T., Ikeda, Y., Shimazu, K., & Uesugi, T. (2001) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(01)80133-5 · Cited by 13
Effect of VDR gene polymorphisms on osteocalcin secretion in calcitriol-stimulated human osteoblasts
Naves‐Díaz, M., Álvarez-Hernández, D., Martín, J. L. F., Paz-Jiménez, J., García-Prado, P., Fernández‐Coto, T., Santamaría, Í., & Cannata-Andía, J. B. (2003) · Kidney International · doi:10.1046/j.1523-1755.63.s85.7.x · Cited by 12
ACE inhibitors and AT1 receptor antagonists: Is two better than one?
Noris, M., & Remuzzi, G. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00261.x · Cited by 12
Management of Lupus Nephropathy
Hebert, L. A. (2003) · Nephron Clinical Practice · doi:10.1159/000066645 · Cited by 11
Self-citation
Target blood pressure for antihypertensive therapy in patients with proteinuric renal disease
Hebert, L. A. (1999) · Current Hypertension Reports · doi:10.1007/s11906-999-0063-0 · Cited by 7
Self-citation
SELECTIVITY AS A CLUE TO DIAGNOSIS OF POSTURAL PROTEINURIA
Fj, F., Frey, B., Koegel, R., Hodler, J., & Wegmüller, E. (1979) · The Lancet · doi:10.1016/s0140-6736(79)92888-5 · Cited by 7

Sorted by citations

Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S. M., Prosek, J. M., Nádasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,392
Self-citation
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
Erratum: The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)
Ogihara, T., Kikuchi, K. M., Matsuoka, H., Fujita, T., Higaki, J., Horiuchi, M., Imai, Y., Imaizumi, T., Ito, S., Iwao, H., et al. (2014) · Hypertension Research · doi:10.1038/hr.2014.68 · Cited by 1,384
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
KDIGO Clinical Practice Guideline for Glomerulonephritis
Eckardt, K., & Kasiske, B. L. (2012) · Cited by 863

See all 217

Authors: Wilmer, W. A., Rovin, B. H., Hebert, C. J., Rao, S. V., Kumor, K., & Hebert, L. A.
Affiliations: The Ohio State University Wexner Medical Center (US)
Louis Stokes Cleveland VA Medical Center (US)
Duke University (US)
Alexion Pharmaceuticals (United States) (US)
Corresponding author: Wilmer, William A.
Rovin, Brad H.
Hebert, Lee A.
ORCID: Rovin, Brad H.
Rao, Sunil V.
Venue: Journal of the American Society of Nephrology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2003-12
Volume: 14
Issue: 12
Pages: 3217-3232
ISSN: 1046-6673 (ISSN-L)
DOI: 10.1097/01.asn.0000100145.27188.33
OpenAlex: W2110754607
Cited by: 217
References: 168
Citations by year: 2026: 1 · 2025: 5 · 2024: 3 · 2023: 4 · 2022: 6 · 2021: 7 · 2020: 3 · 2019: 8 · 2018: 3 · 2017: 4 · 2016: 7 · 2015: 8 · 2014: 6 · 2013: 19 · 2012: 14
FWCI: 10.93
Type: journal article
Language: en
Open access: closed
Locations: Journal of the American Society of Nephrology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5u01dk039485-05)
National Institute of Diabetes and Digestive and Kidney Diseases (P01-DK55546, P01DK055546, U10 DK 48621, U01 DK 39485)
National Center for Research Resources (M01-RR-00034, M01RR000034)
Topics: Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords: glomerular proteinuria, proteinuria reduction, chronic kidney disease, renal protection, antiproteinuric therapy, ACE inhibitors, angiotensin receptor blockers, evidence-based recommendations, pathophysiological mechanisms
MeSH terms: Humans, Kidney Diseases, Kidney Glomerulus, Monitoring, Physiologic, Proteinuria, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Management of Glomerular Proteinuria: A Commentary

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks